59826-28-7 Usage
Description
3-Pyridinecarbonyl chloride, 1,2,5,6-tetrahydro-1-methyl(9CI) is an organic compound with the molecular formula C11H12BrN2O and is characterized by its unique chemical structure. It is a derivative of pyridinecarbonyl chloride and is known for its potential applications in the pharmaceutical and chemical industries due to its versatile chemical properties.
Uses
Used in Pharmaceutical Industry:
3-Pyridinecarbonyl chloride, 1,2,5,6-tetrahydro-1-methyl(9CI) is used as a key intermediate in the synthesis of various pharmaceutical compounds. It plays a crucial role in the development of 6-substituted-4-(3-bromophenylamino)quinazoline derivatives, which function as irreversible inhibitors of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases. These inhibitors are essential in the treatment of various types of cancer, as they help in controlling the unregulated cell growth associated with tumor development.
Additionally, 3-Pyridinecarbonyl chloride, 1,2,5,6-tetrahydro-1-methyl(9CI) is used in the synthesis of Arecaidine But-2-ynyl Ester Tosylate (A767018), a potent and selective muscarinic acetylcholine receptor M2 (mAChR M2) activator. 3-Pyridinecarbonyl chloride, 1,2,5,6-tetrahydro-1-methyl(9CI) has potential applications in the treatment of various neurological and neurodegenerative disorders, such as Alzheimer's disease, by modulating the cholinergic system and enhancing cognitive function.
Check Digit Verification of cas no
The CAS Registry Mumber 59826-28-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,9,8,2 and 6 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 59826-28:
(7*5)+(6*9)+(5*8)+(4*2)+(3*6)+(2*2)+(1*8)=167
167 % 10 = 7
So 59826-28-7 is a valid CAS Registry Number.
59826-28-7Relevant articles and documents
New carbamoylpiperidines as human platelet aggregation inhibitors
Guo, Zhengming,Zheng, Xiaozhang,Thompson, Walter,Dugdale, Marion,Gollamudi, Ram
, p. 1041 - 1058 (2000)
A series of 3-carbamoylpiperidines (nipecotamides) are designed, synthesized and tested for their inhibitory action against adenosine diphosphate (ADP)-induced aggregation of human platelets. A structure- activity analysis of the bis(nipecotamido)aralkane type showed that a substituent on the piperidine ring should preferably be an amide and that the electronegativity of the carbonyl oxygen and the orientation of the amide group affected activities. Based on the knowledge of factors influencing platelet activation and aggregation, a nitric ester moiety which could release nitric oxide (NO) in situ, is incorporated into the nipecotamide structure. These compounds exhibit increased activity compared to those having no -ONO2 function. They also show stereoselectivity, with the meso isomer being approximately twice as potent as the synthetic diastereomeric mixture. Replacement of the -ONO2 function with hydroxyl, ester or alkyl groups considerably diminishes aggregation-inhibitory potential. Nipecotamides are shown here to inhibit the basal and collagen-induced rise in platelet inositol trisphosphate (IP3) levels, as well as phosphoinositide turnover. A comprehensive mechanism of action is proposed taking earlier results into consideration. (C) 2000 Elsevier Science Ltd.
